Sui Z, Zhang X, Li H, Xu D, Li G (2021) Magnetic resonance imaging evaluation of brain glioma before postoperative radiotherapy. Clin Transl Oncol 23:820–826
Clarke RH, Moosa S, Anzivino M, Wang Y, Floyd DH et al (2014) Sustained radiosensitization of hypoxic glioma cells after oxygen pretreatment in an animal model of glioblastoma and in vitro models of tumor hypoxia. PLoS ONE 9:e111199
Toyonaga T, Hirata K, Shiga T, Nagara T (2017) Players of “hypoxia orchestra” - what is the role of FMISO? Eur J Nucl Med Mol Imaging 44:1679–1681
Mudassar F, Shen H, O’Neill G, Hau E (2020) Targeting tumor hypoxia and mitochondrial metabolism with anti-parasitic drugs to improve radiation response in high-grade gliomas. J Exp Clin Cancer Res 39:208
Hua L, Wang Z, Zhao L, Mao H, Wang G et al (2018) Hypoxia-responsive lipid-poly-(hypoxic radiosensitized polyprodrug) nanoparticles for glioma chemo- and radiotherapy. Theranostics 8:5088–5105
Horsman MR, Mortensen LS, Petersen JB, Busk M, Overgaard J (2012) Imaging hypoxia to improve radiotherapy outcome. Nat Rev Clin Oncol 9:674–687
Qi R, Jin W, Wang J, Yi Q, Yu M et al (2014) Oleanolic acid enhances the radiosensitivity of tumor cells under mimetic hypoxia through the reduction in intracellular GSH content and HIF-1alpha expression. Oncol Rep 31:2399–2406
Gao D, Tang S, Tong Q (2012) Oleanolic acid liposomes with polyethylene glycol modification: promising antitumor drug delivery. Int J Nanomed 7:3517–3526
Fahrni G, Karakatsanis NA, Di Domenicantonio G, Garibotto V, Zaidi H (2019) Does whole-body Patlak (18)F-FDG PET imaging improve lesion detectability in clinical oncology? Eur Radiol 29:4812–4821
Cheebsumon P, Velasquez LM, Hoekstra CJ, Hayes W, Kloet RW et al (2011) Measuring response to therapy using FDG PET: semi-quantitative and full kinetic analysis. Eur J Nucl Med Mol Imaging 38:832–842
Bartlett RM, Beattie BJ, Naryanan M, Georgi JC, Chen Q et al (2012) Image-guided PO2 probe measurements correlated with parametric images derived from 18F-fluoromisonidazole small-animal PET data in rats. J Nucl Med 53:1608–1615
van der Weerdt AP, Klein LJ, Boellaard R, Visser CA, Visser FC et al (2001) Image-derived input functions for determination of MRGlu in cardiac (18)F-FDG PET scans. J Nucl Med 42:1622–1629
Freedman NM, Sundaram SK, Kurdziel K, Carrasquillo JA, Whatley M et al (2003) Comparison of SUV and Patlak slope for monitoring of cancer therapy using serial PET scans. Eur J Nucl Med Mol Imaging 30:46–53
Ali MY, Oliva CR, Noman A, Allen BG, Goswami PC et al (2020) Radioresistance in glioblastoma and the development of radiosensitizers. Cancers (Basel) 12:2511
Abdo RA, Lamare F, Fernandez P, Bentourkia M (2019) Analysis of hypoxia in human glioblastoma tumors with dynamic 18F-FMISO PET imaging. Australas Phys Eng Sci Med 42:981–993
Chedeville AL, Madureira PA (2021) The role of hypoxia in glioblastoma radiotherapy resistance. Cancers (Basel) 13:542
Gong L, Zhang Y, Liu C, Zhang M, Han S (2021) Application of radiosensitizers in cancer radiotherapy. Int J Nanomedicine 16:1083–1102
Wang J, Yu M, Xiao L, Xu S, Yi Q et al (2013) Radiosensitizing effect of oleanolic acid on tumor cells through the inhibition of GSH synthesis in vitro. Oncol Rep 30:917–924
Rahmim A, Lodge MA, Karakatsanis NA, Panin VY, Zhou Y et al (2019) Dynamic whole-body PET imaging: principles, potentials and applications. Eur J Nucl Med Mol Imaging 46:501–518
van Sluis J, Yaqub M, Brouwers AH, Dierckx R, Noordzij W et al (2021) Use of population input functions for reduced scan duration whole-body Patlak (18)F-FDG PET imaging. EJNMMI Phys 8:11
Karakatsanis NA, Zhou Y, Lodge MA, Casey ME, Wahl RL et al (2015) Generalized whole-body Patlak parametric imaging for enhanced quantification in clinical PET. Phys Med Bio 60:8643–8673
Patlak CS, Blasberg RG (1983) Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab 3:1–7
Masaki Y, Shimizu Y, Yoshioka T, Nishijima KI, Zhao S et al (2017) FMISO accumulation in tumor is dependent on glutathione conjugation capacity in addition to hypoxic state. Ann Nucl Med 31:596–604
Toyonaga T, Hirata K, Yamaguchi S, Hatanaka KC, Yuzawa S et al (2016) (18)F-fluoromisonidazole positron emission tomography can predict pathological necrosis of brain tumors. Eur J Nucl Med Mol Imaging 43:1469–1476
Toyonaga T, Yamaguchi S, Hirata K, Kobayashi K, Manabe O et al (2017) Hypoxic glucose metabolism in glioblastoma as a potential prognostic factor. Eur J Nucl Med Mol Imaging 44:611–619
Eschmann SM, Paulsen F, Reimold M, Dittmann H, Welz S et al (2005) Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med 46:253–260
Gagel B, Piroth M, Pinkawa M, Reinartz P, Zimny M et al (2007) pO polarography, contrast enhanced color duplex sonography (CDS), [18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography: validated methods for the evaluation of therapy-relevant tumor oxygenation or only bricks in the puzzle of tumor hypoxia? BMC Cancer 7:113
Jiang BH, Semenza GL, Bauer C, Marti HH (1996) Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O2 tension. Am J Physiol-Cell Ph 271:C1172–C1180
Sun J, Chen C, Wei W, Zheng H, Yuan J et al (2015) Associations and indications of Ki67 expression with clinicopathological parameters and molecular subtypes in invasive breast cancer: a population-based study. Oncol Lett 10:1741–1748
Takahashi M, Nojima H, Kuboki S, Horikoshi T, Yokota T et al (2020) Comparing prognostic factors of Glut-1 expression and maximum standardized uptake value by FDG-PET in patients with resectable pancreatic cancer. Pancreatology 20:1205–1212
留言 (0)